Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (4919)	11/28/1997 4:39:00 PM
From: Edward Paule	Read Replies (1) \| Respond to of 17367

What's the magic number? I know that most mutual funds and indexes don't touch stocks below a certain market cap; either by choice or by charter. I assume that there is no one magic number that everybody plays by. But is there general concensus around a particular zone? Basically, if XOMA dips below $250M (currently at $270M), will we be in danger of loosing some major support? Here's my $0.02. My wife has a majority of her 401k savings tied up in Fidelity Magellan. Ergo, I receive their periodic reports. Each time one comes in, I check out their "Drug & Pharmaceuticals" stock holdings for any Biotechs. For many years, this was boring. It was always the same, Genentech and Amgen, Genentech and Amgen, Genentech and Amgen. But this pattern changed recently. Around a year ago (major wag), they dumped Amgen. Good move. Then in their most recent report (9/30/97), I saw some new names: Alkermes ($400M market cap), Gilead ($1B), and Hyseq ($160M). Not knowing when Fidelity Magellan actually bought the stock, Hyseq's 52-week high only brings a market cap of $273M. I find the Alkermes and Hyseq holdings in such an enormous fund to be pleasantly surprising.